吉西他滨联合替吉奥治疗蒽环类耐药晚期乳腺癌的效果

Efficacy of Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium in the treatment of Anthracycline resistant advanced breast cancer

目的探讨吉西他滨联合替吉奥治疗蒽环类耐药晚期乳腺癌的效果。方法选取2015年8月～2017年8月我院收治的60例蒽环类耐药晚期乳腺癌患者作为研究对象,按照治疗方法的不同,将其分为对照组(30例)与观察组(30例)。对照组患者采用吉西他滨注射液,观察组患者采用吉西他滨联合替吉奥方案。比较两组患者的治疗总有效率、毒副作用发生率和治疗前后卡氏(KPS)评分与数字评分法(NRS)评分。结果观察组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者的毒副作用Ⅰ级发生率为33.3%,毒副作用Ⅱ级发生率为40.0%,高于对照组的10.0%和16.3%,毒副作用Ⅲ级发生率低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前的KPS评分、NRS评分比较,差异无统计学意义(P>0.05);观察组患者治疗后的KPS评分明显高于对照组,NRS评分明显低于对照组,差异有统计学意义(P<0.05)。结论蒽环类耐药晚期乳腺癌患者使用吉西他滨联合替吉奥治疗方案,临床效果好,毒副作用小,可改善体力状况,缓解疼痛感,值得深入研讨,并在此基础上展开推广应用。

Objective To investigate the efficacy of Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium in the treatment of Anthracycline resistant advanced breast cancer. Methods A total of 60 patients with Anthracycline resistant advanced breast cancer admitted in our hospital from August 2015 to August 2017 were selected as subjects. According to different treatment methods, they were divided into control group (30 cases) and observation group (30 cases). The control group was treated with Gemcitabine Injection. The observation group was treated with Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium. The total effective rate, toxic side effect rate, Kamofsky performance status (KPS) score and numerical raing scale (NRS) score before and after treatment were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the significance of calculation was significant (P<0.05). The incidence of side effects Ⅰ level in the observation group was 33.3%, the incidence of toxic side effects Ⅱ level was 40.0%, which were higher than those of the control group (10.0% and 16.3%), the incidence of toxic side effects Ⅲ level was lower than that in the control group, the differences were statistically significant (P<0.05). There was no significant difference in KPS score and NRS score between the two groups before treatment (P>0.05), but the KPS score in the observation group was significantly higher than that in the control group, and the NRS score in the observation group was significantly lower than that in the control group (P<0.05). Conclusion Anthracycline resistant advanced breast cancer patients using Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium treatment regimen, the clinical effect is good, the toxic side effects are small, can improve physical conditions, alleviate the pain, it is worth in-depth research, and on this basis to promote the application.